【丹麦】诺和诺德基金会与英伟达联手打造AI超级计算机，开启新药研发新篇章
当地时间3月18日，国际知名的医药巨头诺和诺德基金会宣布了一项重大创新举措，将与全球领先的图形处理器制造商英伟达合作，在丹麦建设一座名为Gefion的先进人工智能超级计算机。这台超级计算机将充分利用英伟达的尖端AI技术，旨在加速新药和疗法的发现过程，为全球医疗健康领域带来革命性的突破。
Gefion的建立将为丹麦的公共和私营部门研究人员提供一个强大的计算平台，帮助他们在生物医学研究中进行更为精准和高效的模拟与数据分析。通过AI的深度学习能力，科研人员有望在药物研发的早期阶段就能预测分子结构、评估潜在疗效和副作用，从而大大缩短新药上市的时间，降低研发成本。
诺和诺德基金会表示，这一合作项目不仅将推动丹麦在生命科学领域的领先地位，还将为全球医药产业树立新的标杆。英伟达的AI技术在处理复杂数据和模拟方面的能力，与诺和诺德在生物制药领域的深厚积累相结合，有望催生出更多创新疗法，为全球患者带来福音。
这一合作计划的宣布，标志着科技与医药行业的深度融合进入了一个新的阶段，预示着未来医疗领域的研究将更加依赖于高级计算和人工智能的支持。随着Gefion的建设，我们期待看到更多的新药和疗法在更短的时间内面世，以应对全球公共卫生挑战。
英语如下：
**News Title:** “Novo Nordisk Foundation and NVIDIA Team Up: Denmark to Build AI Supercomputer for Accelerating New Drug Development”
**Keywords:** AI Supercomputer, Novo Nordisk, Drug Discovery
**News Content:**
**Denmark** – The Novo Nordisk Foundation, a renowned international pharmaceutical giant, has announced a major innovation initiative in collaboration with NVIDIA, the world’s leading graphics processing unit manufacturer. The partnership will result in the construction of an advanced artificial intelligence (AI) supercomputer named Gefion in Denmark, ushering in a new era in drug discovery.
On March 18th, the Foundation disclosed that Gefion, leveraging NVIDIA’s cutting-edge AI technology, is aimed at expediting the discovery and development of new drugs and therapies, potentially revolutionizing the global healthcare landscape.
The establishment of Gefion will provide a powerful computing platform for both public and private sector researchers in Denmark, enabling more precise and efficient simulations and data analysis in biomedical research. By harnessing the deep learning capabilities of AI, scientists could predict molecular structures, assess potential efficacy and side effects at earlier stages of drug development, thereby shortening the time to market and reducing R&D costs.
The Novo Nordisk Foundation asserts that this collaboration will not only reinforce Denmark’s position at the forefront of life sciences but also set new standards for the global pharmaceutical industry. The combination of NVIDIA’s AI prowess in handling complex data and simulations with Novo Nordisk’s extensive expertise in biopharmaceuticals is anticipated to spawn more innovative treatments, benefiting patients worldwide.
This partnership announcement signals a new chapter in the convergence of technology and the pharmaceutical sector, indicating that future medical research will increasingly rely on advanced computing and AI support. With the construction of Gefion, the world eagerly awaits the accelerated development of new drugs and therapies to address global public health challenges.
【来源】https://www.chinastarmarket.cn/detail/1624366
Views: 1